Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Progression‐free survival · people with metastatic CRC

Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.71 [0.64, 0.79]
2 studies · 1758 participants
Moderate